Where Opus Genetics Stands With Analysts
6 analysts have shared their evaluations of Opus Genetics (NASDAQ:IRD) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 1 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $8.0, a high estimate of $9.00, and a low estimate of $7.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.96%.
Interpreting Analyst Ratings: A Closer Look
The perception of Opus Genetics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Thomas Shrader | BTIG | Maintains | Buy | $7.00 | $7.00 |
| Thomas Shrader | BTIG | Announces | Buy | $7.00 | - |
| Mayank Mamtani | B. Riley Securities | Announces | Buy | $9.00 | - |
| Biren Amin | Piper Sandler | Announces | Overweight | $7.00 | - |
| Daniil Gataulin | Chardan Capital | Maintains | Buy | $9.00 | $9.00 |
| Daniil Gataulin | Chardan Capital | Maintains | Buy | $9.00 | $9.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Opus Genetics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Opus Genetics compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Opus Genetics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Opus Genetics's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Opus Genetics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering Opus Genetics: A Closer Look
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Opus Genetics: A Financial Overview
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Challenges: Opus Genetics's revenue growth over 3M faced difficulties. As of 30 September, 2025, the company experienced a decline of approximately -20.38%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Opus Genetics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -566.87%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Opus Genetics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -148.92%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -46.68%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.18, Opus Genetics adopts a prudent financial strategy, indicating a balanced approach to debt management.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.